Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system

Immunological Reviews(2022)10.1111/imr.13164Source: DataRank Database

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system is a research paper published in Immunological Reviews (2022). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

Linked data & code

nct doi pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.66)OA: hybridTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Richard J. Smith ORCID,Christoph Q. Schmidt ORCID

Live enrichment

PubMed:36398537 PMC:PMC9852015 OpenAlex:https://openalex.org/W4309280962

Deutsche Forschungsgemeinschaft

Grant: DFG.4372

Deutsche Forschungsgemeinschaft

Grant: DFG.5696

Deutsche Forschungsgemeinschaft

Grant: DFG.6821

National Institutes of Health

Grant: NIDDK R01 110023

NIDDK NIH HHS

Grant: R01 DK110023

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

FWCI

1.66

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imr.13164

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imr.13164

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/imr.13164

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/imr.13164

journalhttps://doi.org/10.1111/imr.13164

Fields of Study

Complement system in diseasesRenal Diseases and GlomerulopathiesAdenosine and Purinergic Signaling0301 basic medicine03 medical and health sciences0302 clinical medicineHumansComplement System ProteinsComplement ActivationHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic SyndromeComplement C5Complement Inactivating Agents

MeSH Terms

Complement System ProteinsComplement ActivationComplement C5Hemoglobinuria, ParoxysmalHumansComplement Inactivating AgentsAtypical Hemolytic Uremic Syndrome

Keywords

EculizumabAtypical hemolytic uremic syndromeComplement systemComplement component 5AnaphylatoxinParoxysmal nocturnal hemoglobinuriaComplement membrane attack complexImmunologyComplement (music)Neuromyelitis opticaCD59Complement deficiencyAntibodyMedicineBiologyPhenotypeGeneticsAlternative pathwayComplement TherapeuticsComplement Protein InhibitorsMechanistic Foundations Of Complementinfo:eu-repo/classification/ddc/570Hemoglobinuria, ParoxysmalKomplement C5Complement C5Complement System ProteinsKomplement <Immunologie>Monoklonaler AntikörperAntibodies; Therapeutic useImmuntherapieComplement Inactivating AgentsComplement system proteins; Drug effectsHumansComplement Activationinfo:eu-repo/classification/ddc/610

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system

FAIR Checklist

Authors (2)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)